Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2023-12-22 · accession 0001453687-24-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | RNAC | Singer Michael | Dir, 10% | A - Grant | $0.00 | +178.0K | 288.1K | +162% | $0 |
| D | 2024-01-04 | 2024-01-02 | RNAC | Singer Michael | Dir, 10% | A - Grant | $0.00 | +228.0K | 228.0K | New | $0 |
| D | 2024-01-04 | 2023-12-22 | RNAC | Singer Michael | Dir, 10% | G - Gift | $0.00 | -3,000 | 3,305 | -48% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | A | A | 178,000 | $0.00 | 288,123 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-02 | A | A | 228,000 | $0.00 | 228,000 | D | $0.66 · — to 2034-01-01 | 228,000 Common Stock | (F8) This award will vest in 36 equal monthly installments, so that it shall be fully vested on the third anniversary of the date of grant. |
| 3 | Derivative | Series A Convertible Preferred Stock | 2023-12-22 | G | D | 3,000 | $0.00 | 3,304.56 | D | — · — to — | 3,000,000 Common Stock | (F9) Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. |